Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Preexposure prophylaxis for HIV infection.

Steinbrook R.

JAMA. 2012 Sep 5;308(9):865-6. doi: 10.1001/jama.2012.9885. No abstract available.

PMID:
22820712
2.

Ethical challenges of preexposure prophylaxis for HIV.

Jay JS, Gostin LO.

JAMA. 2012 Sep 5;308(9):867-8. doi: 10.1001/2012.jama.10158. No abstract available.

PMID:
22847147
3.

Preexposure prophylaxis: An emerging clinical approach to preventing HIV in high-risk adults.

Blackwell CW.

Nurse Pract. 2014 Sep 18;39(9):50-3. doi: 10.1097/01.NPR.0000452976.92052.fa. Review.

PMID:
25140852
4.

Interim guidance for clinicians considering the use of preexposure prophylaxis for the prevention of HIV infection in heterosexually active adults.

Centers for Disease Control and Prevention (CDC)..

MMWR Morb Mortal Wkly Rep. 2012 Aug 10;61(31):586-9.

5.

Emtricitabine/tenofovir (Truvada) for HIV prophylaxis.

Coutinho B, Prasad R.

Am Fam Physician. 2013 Oct 15;88(8):535-40. Review. No abstract available.

6.

Role of oral pre-exposure prophylaxis (PrEP) in current and future HIV prevention strategies.

Burns DN, Grossman C, Turpin J, Elharrar V, Veronese F.

Curr HIV/AIDS Rep. 2014 Dec;11(4):393-403. doi: 10.1007/s11904-014-0234-8. Review.

PMID:
25283184
7.

Infectious diseases. Doubts dispelled about HIV prevention.

Cohen J.

Science. 2015 Mar 6;347(6226):1055-6. doi: 10.1126/science.347.6226.1055. No abstract available.

PMID:
25745140
8.

How good is "good enough"? The case for varying standards of evidence according to need for new interventions in HIV prevention.

Haire B, Kaldor J, Jordens CF.

Am J Bioeth. 2012;12(6):21-30. doi: 10.1080/15265161.2012.671887.

PMID:
22650457
9.

Recent FDA approvals and changes.

[No authors listed]

AIDS Patient Care STDS. 2010 Feb;24(2):133-4. doi: 10.1089/apc.2010.9911. No abstract available.

PMID:
20156092
10.

A perspective on progress and gaps in HIV prevention science.

Kiser PF, Mesquita PM, Herold BC.

AIDS Res Hum Retroviruses. 2012 Nov;28(11):1373-8. doi: 10.1089/AID.2012.0277.

11.

Intentions to prescribe preexposure prophylaxis are associated with self-efficacy and normative beliefs.

Sachdev DD, Stojanovski K, Liu AY, Buchbinder SP, Macalino GE.

Clin Infect Dis. 2014 Jun;58(12):1786-7. doi: 10.1093/cid/ciu229. Epub 2014 Apr 12. No abstract available.

12.

FDA paves the way for pre-exposure HIV prophylaxis.

Holmes D.

Lancet. 2012 Jul 28;380(9839):325. No abstract available.

PMID:
22852138
13.

Single-tablet Quad regimen achieves high rate of virologic suppression.

[No authors listed]

AIDS Patient Care STDS. 2010 Mar;24(3):197. doi: 10.1089/apc.2010.9909. No abstract available.

PMID:
20214488
14.

Emtricitabine + tenofovir to prevent HIV transmission. More evaluation needed.

[No authors listed]

Prescrire Int. 2013 Jul;22(140):178-81.

PMID:
23951592
15.

Antiretroviral prophylaxis: a defining moment in HIV control.

Karim SS, Karim QA.

Lancet. 2011 Dec 17;378(9809):e23-5. doi: 10.1016/S0140-6736(11)61136-7. Epub 2011 Jul 21. No abstract available.

16.

Emtricitabine/tenofovir disoproxil fumarate.

Dando TM, Wagstaff AJ.

Drugs. 2004;64(18):2075-82; discussion 2083-4. Review.

PMID:
15341498
17.

Trial success spurs planning for rollout of HIV prevention pills.

Dolgin E.

Nat Med. 2011 Apr;17(4):392. doi: 10.1038/nm0411-392. No abstract available.

PMID:
21475207
18.

Study halted: no benefit seen from antiretroviral pill in preventing HIV in women.

Stephenson J.

JAMA. 2011 May 18;305(19):1952. doi: 10.1001/jama.2011.649. No abstract available.

PMID:
21586708
19.

The Truvada wars.

Belluz J.

BMJ. 2014 Jun 24;348:g3811. doi: 10.1136/bmj.g3811. No abstract available.

PMID:
24961949
20.

Reply to Sachdev et al.

Karris MY, Beekmann SE, Mehta SR, Polgreen PM.

Clin Infect Dis. 2014 Jun;58(12):1788. doi: 10.1093/cid/ciu231. Epub 2014 Apr 12. No abstract available.

Supplemental Content

Support Center